Sigilon Therapeutics to Present at Upcoming Conferences

CAMBRIDGE, Mass., Feb. 8, 2018 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:

    BIO CEO & Investor Conference 2018


    Presenter:                                      Paul Wotton, Ph.D., Chief
                                                    Executive Officer

    Date:                                          Monday, Feb. 12, 2018

    Time:                                          10:15 a.m. EST

    Location:                                       Room Gilbert, New York
                                                    Marriott Marquis Hotel,
                                                    New York

    Biocom Global Life Science Partnering Conference 2018


    Panel presentation:                             What to Expect in Business
                                                    Development: 2018 & Beyond

    Presenter:                                      David Moller, M.D., Chief
                                                    Scientific Officer

    Date:                                          Thursday, March 1, 2018

    Time:                                          8:30 a.m. PST

    Location:                                       Maurice Braun ballroom, The Lodge
                                                    at Torrey Pines Hotel, La Jolla,
                                                    CA

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromer(TM) technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

View original content:http://www.prnewswire.com/news-releases/sigilon-therapeutics-to-present-at-upcoming-conferences-300595664.html

SOURCE Sigilon Therapeutics